Last Updated: 16 Sep 2024
Executive Summary
Intracellular Th (ITCI) is a biopharmaceutical company focused on developing treatments for neuropsychiatric and neurological diseases. The company's latest stock price is $75.38. Analysts are generally bullish on ITCI, with 14 out of 17 analysts recommending a buy or strong buy. The company's strong revenue growth and promising pipeline of drugs are key factors driving analyst optimism.
Company Overview
Intra-Cellular Therapies, Inc. is a biopharmaceutical company that develops new drugs for the treatment of neuropsychiatric and neurological diseases and other central nervous system (CNS) disorders. The company's lead product candidate, ITI-007, is a novel, oral, small molecule that is being developed for the treatment of schizophrenia and bipolar disorder. ITI-007 has shown promising results in clinical trials, and the company is currently conducting a Phase 3 clinical trial to evaluate the drug's efficacy and safety.
Fundamental Analysis
ITCI's financial performance has been mixed in recent years. The company reported revenue of $564.5 million in the last twelve months, an increase of 45.7% year-over-year. However, the company also reported a net loss of $111.9 million in the last twelve months, and its earnings per share (EPS) were -$0.86. ITCI's balance sheet is relatively strong, with $335.9 million in cash and equivalents and no long-term debt.
Technical Analysis
ITCI's stock price has been in a strong uptrend in recent months. The stock has broken above its 50-day and 200-day moving averages, and it is now trading near its 52-week high. The stock's relative strength index (RSI) is also in bullish territory, indicating that the stock is overbought.
Short Term Outlook
In the short term, ITCI's stock price is likely to continue to rise. The company's strong financial performance and promising pipeline of drugs are likely to continue to attract investors. The stock's technical indicators are also bullish, suggesting that the stock is likely to continue to move higher in the near term.
Long Term Outlook
In the long term, ITCI's stock price is likely to be driven by the success of its clinical trials. If ITI-007 is approved by the FDA, it could be a major blockbuster drug for the company. ITCI also has a number of other promising drugs in its pipeline, which could provide further upside for the stock in the long term.
Analyst Recommendations
Analysts are generally bullish on ITCI. The consensus analyst rating is a buy, and the average analyst target price is $95.84. Fourteen out of seventeen analysts recommend a buy or strong buy for the stock.
